Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Licitra

Showing results (241-250 of 311) with videos related to

Pageof 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid CancerLori J Wirth, Marcia S Brose, Eric J Sherman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2009
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]J Simon W Stewart, Ezra E W Cohen, Lisa Licitra, et al.
Medrxiv : the Preprint Server for Health Sciences|September 25, 2023
A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinomaEmily Ho, Loris De Cecco, Stefano Cavalieri, et al.
Oral Oncology|October 1, 2023
Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experienceStefano Cavalieri, Francesca Platini, Francesco Barretta, et al.
The Laryngoscope|August 2, 2019
Locally advanced epithelial sinonasal tumors: The impact of multimodal approachEster Orlandi, Stefano Cavalieri, Roberta Granata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2019
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab UseRobert L Ferris, Lisa Licitra, Jerome Fayette, et al.
Cancers|April 15, 2020
Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell CarcinomaSalvatore Alfieri, Andrea Carenzo, Francesca Platini, et al.
The Lancet. Oncology|May 19, 2015
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, et al.
The Lancet. Oncology|June 11, 2013
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialJan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, et al.
Future Oncology (London, England)|March 28, 2023
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)Stefano Cavalieri, Viviana Vitolo, Amelia Barcellini, et al.
Pageof 32

Showing results (241-250 of 311) with videos related to

Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid CancerLori J Wirth, Marcia S Brose, Eric J Sherman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2009
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]J Simon W Stewart, Ezra E W Cohen, Lisa Licitra, et al.
Medrxiv : the Preprint Server for Health Sciences|September 25, 2023
A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinomaEmily Ho, Loris De Cecco, Stefano Cavalieri, et al.
Oral Oncology|October 1, 2023
Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experienceStefano Cavalieri, Francesca Platini, Francesco Barretta, et al.
The Laryngoscope|August 2, 2019
Locally advanced epithelial sinonasal tumors: The impact of multimodal approachEster Orlandi, Stefano Cavalieri, Roberta Granata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2019
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab UseRobert L Ferris, Lisa Licitra, Jerome Fayette, et al.
Cancers|April 15, 2020
Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell CarcinomaSalvatore Alfieri, Andrea Carenzo, Francesca Platini, et al.
The Lancet. Oncology|May 19, 2015
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, et al.
The Lancet. Oncology|June 11, 2013
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialJan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, et al.
Future Oncology (London, England)|March 28, 2023
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)Stefano Cavalieri, Viviana Vitolo, Amelia Barcellini, et al.
Pageof 32